Clinical Trial Update: Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes evaluation of the PET tracer [18F]AlF-NOTA-PCP2 for PD-L1 detection across malignant tumors, including glioblastoma, head a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Glioblastoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• [18F]AlF-NOTA-PCP2 (18F-AlF-NOTA-PCP2 radiotracer)

Snippet

Sponsor: Man Hu | Conditions: Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION